Global Health
TABLE OF CONTENTS
Volume 82, Issue 5 (November 2007)
Editorial |
News and Views |
Perspectives |
State of the Art |
Research |
Discovery & Development |
Regulation & Use
Contents
Contents
In this issue FREE
Clin Pharmacol Ther 82: 477; doi:10.1038/sj.clpt.6100412
See also: Macroscopy by DiMasi & GrabowskiSee also: State of the Art by Batsis et al. See also: Discovery by SaavedraSee also: Development by Nyunt & PloweSee also: Ethics by Cohen-KohlerEditorial
Individualized Medicine and the Imperative of Global Health
S A Waldman and A Terzic
Clin Pharmacol Ther 82: 479-483; doi:10.1038/sj.clpt.6100398
News and Views
Highlights
News and Views
Clin Pharmacol Ther 82: 484-485; doi:10.1038/sj.clpt.6100411
ASCPT News
ASCPT News
Clin Pharmacol Ther 82: 486-487; doi:10.1038/sj.clpt.6100413
Macroscopy
Should the Patent System for New Medicines Be Abolished?
J A DiMasi and H G Grabowski
Clin Pharmacol Ther 82: 488-490; doi:10.1038/sj.clpt.6100393
A Vision of Individualized Medicine in the Context of Global Health FREE
D A Cortese
Clin Pharmacol Ther 82: 491-493; doi:10.1038/sj.clpt.6100390
Perspectives
Commentaries
Does Clinical Pharmacology & Therapeutics' Conflict of Interest Policy Protect the Reader?
M H Conway
Clin Pharmacol Ther 82: 495-496; doi:10.1038/sj.clpt.6100387
See also: Commentary byClinical Pharmacology & Therapeutics' Conflict of Interest Policy
Clin Pharmacol Ther 82: 496-497; doi:10.1038/sj.clpt.6100414
See also: Commentary by ConwayThe Essential Medicines List for a Global Patient Population FREE
J Robertson and S R Hill
Clin Pharmacol Ther 82: 498-500; doi:10.1038/sj.clpt.6100392
Essential Medicines for the Whole World
M M Reidenberg
Clin Pharmacol Ther 82: 500-503; doi:10.1038/sj.clpt.6100388
Access to Essential Medicines for Children: The World Health Organization's Global Response
H Zucker and L Rägo
Clin Pharmacol Ther 82: 503-505; doi:10.1038/sj.clpt.6100395
Dosing in Obesity: A Simple Solution to a Big Problem
P Y Han, S B Duffull, C M J Kirkpatrick and B Green
Clin Pharmacol Ther 82: 505-508; doi:10.1038/sj.clpt.6100381
State of the Art
State of the Art
Metabolic Syndrome: From Global Epidemiology to Individualized Medicine
J A Batsis, R E Nieto-Martinez and F Lopez-Jimenez
Clin Pharmacol Ther 82: 509-524; advance online publication, September 12, 2007; doi:10.1038/sj.clpt.6100355
Research
Articles
Presynaptic 
-2C Adrenoceptor-mediated Control of Noradrenaline Release in Humans: Genotype- or Age-Dependent?
H Bruck, T Schwerdtfeger, M Toliat, K Leineweber, G Heusch, T Philipp, P Nürnberg and O-E Brodde
Clin Pharmacol Ther 82: 525-530; advance online publication, April 4, 2007; doi:10.1038/sj.clpt.6100181
Development of the "Inje Cocktail" for High-throughput Evaluation of Five Human Cytochrome P450 Isoforms in vivo
J Y Ryu, I S Song, Y E Sunwoo, J H Shon, K H Liu, I J Cha and J G Shin
Clin Pharmacol Ther 82: 531-540; advance online publication, March 28, 2007; doi:10.1038/sj.clpt.6100187
SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers
I Ieiri, S Suwannakul, K Maeda, H Uchimaru, K Hashimoto, M Kimura, H Fujino, M Hirano, H Kusuhara, S Irie, S Higuchi and Y Sugiyama
Clin Pharmacol Ther 82: 541-547; advance online publication, April 25, 2007; doi:10.1038/sj.clpt.6100190
Comparison of the Effects of Thioridazine and Mesoridazine on the QT Interval in Healthy Adults After Single Oral Doses
I S M Salih, R H K Thanacoody, G A McKay and S H L Thomas
Clin Pharmacol Ther 82: 548-554; advance online publication, April 4, 2007; doi:10.1038/sj.clpt.6100194
See also: Article by Thanacoody et al.Factors Affecting Drug Concentrations and QT Interval During Thioridazine Therapy
R H K Thanacoody, A K Daly, J G Reilly, I N Ferrier and S H L Thomas
Clin Pharmacol Ther 82: 555-565; advance online publication, April 25, 2007; doi:10.1038/sj.clpt.6100195
See also: Article by Salih et al.Clinical Pharmacology Information in Summaries of Product Characteristics and Package Inserts
B Arguello and F Fernandez-Llimos
Clin Pharmacol Ther 82: 566-571; advance online publication, April 4, 2007; doi:10.1038/sj.clpt.6100198
Vaporization as a Smokeless Cannabis Delivery System: A Pilot Study
D I Abrams, H P Vizoso, S B Shade, C Jay, M E Kelly and N L Benowitz
Clin Pharmacol Ther 82: 572-578; advance online publication, April 11, 2007; doi:10.1038/sj.clpt.6100200
Cytochrome P450 3A5 Genotype is Associated with Verapamil Response in Healthy Subjects
Y Jin, Y-H Wang, J Miao, L Li, R J Kovacs, R Marunde, M A Hamman, S Phillips, J Hilligoss and S D Hall
Clin Pharmacol Ther 82: 579-585; advance online publication, April 18, 2007; doi:10.1038/sj.clpt.6100208
Discovery & Development
Discovery
Molecular Systems Biology in Drug Development
P A Silver and J C Way
Clin Pharmacol Ther 82: 586-590; advance online publication, July 18, 2007; doi:10.1038/sj.clpt.6100293
Endocannabinoid System and Cardiometabolic Risk FREE
L E Saavedra
Clin Pharmacol Ther 82: 591-594; advance online publication, September 26, 2007; doi:10.1038/sj.clpt.6100373
Translational Medicine
Advances in the Treatment of Tuberculosis
Y Zhang
Clin Pharmacol Ther 82: 595-600; advance online publication, September 26, 2007; doi:10.1038/sj.clpt.6100362
Development
Pharmacologic Advances in the Global Control and Treatment of Malaria: Combination Therapy and Resistance
M M Nyunt and C V Plowe
Clin Pharmacol Ther 82: 601-605; advance online publication, September 26, 2007; doi:10.1038/sj.clpt.6100361
Regulation & Use
Practice
Metabolism of Antidepressant and Neuroleptic Drugs by Cytochrome P450s: Clinical and Interethnic Aspects
L Bertilsson
Clin Pharmacol Ther 82: 606-609; advance online publication, September 26, 2007; doi:10.1038/sj.clpt.6100358
Ethics
The Morally Uncomfortable Global Drug Gap FREE
J C Cohen-Kohler
Clin Pharmacol Ther 82: 610-614; advance online publication, September 26, 2007; doi:10.1038/sj.clpt.6100359
